Literature DB >> 30595119

Mineralocorticoid Receptor Activation and Atrial Fibrosis.

Nancy J Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30595119      PMCID： PMC6404541          DOI： 10.1161/HYPERTENSIONAHA.118.11604

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  10 in total

1.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.

Authors:  Karl Swedberg; Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Harry Shi; John Vincent; Bertram Pitt
Journal:  J Am Coll Cardiol       Date:  2012-05-01       Impact factor: 24.094

2.  Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.

Authors:  Nicolas Verheyen; Martin R Grübler; Andreas Meinitzer; Christian Trummer; Verena Schwetz; Karin Amrein; Hans P Dimai; Winfried März; Cristiana Catena; Dirk von Lewinski; Jakob Voelkl; Ioana Alesutan; Astrid Fahrleitner-Pammer; Helmut Brussee; Stefan Pilz; Andreas Tomaschitz
Journal:  Bone       Date:  2017-09-14       Impact factor: 4.398

3.  Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia.

Authors:  Toshio Fumoto; Kiyo-Aki Ishii; Masako Ito; Stefan Berger; Günther Schütz; Kyoji Ikeda
Journal:  Biochem Biophys Res Commun       Date:  2014-04-05       Impact factor: 3.575

4.  Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone.

Authors:  M S Cooper; E A Walker; R Bland; W D Fraser; M Hewison; P M Stewart
Journal:  Bone       Date:  2000-09       Impact factor: 4.398

5.  Eplerenone Prevents Atrial Fibrosis via the TGF-β Signaling Pathway.

Authors:  Lili Du; Mu Qin; Yi Yi; Xiaoqing Chen; Weifeng Jiang; Li Zhou; Daoliang Zhang; Kai Xu; Yiqing Yang; Chao Li; Yan Liu; Xu Liu; Sheng-Zhong Duan
Journal:  Cardiology       Date:  2017-06-02       Impact factor: 1.869

6.  Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Authors:  Allison L Kuipers; Candace M Kammerer; J Howard Pratt; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Joseph M Zmuda
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

7.  Fracture risk in men with congestive heart failure risk reduction with spironolactone.

Authors:  Laura D Carbone; Jessica D Cross; Syed H Raza; Andrew J Bush; Robert J Sepanski; Saurabh Dhawan; Bilal Q Khan; Malini Gupta; Khurram Ahmad; Rami N Khouzam; Dwight A Dishmon; Joseph P Nesheiwat; Mohammad A Hajjar; Waqas A Chishti; Wael Nasser; Mehwish Khan; Catherine R Womack; Tara Cho; Ashley R Haskin; Karl T Weber
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

8.  Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term.

Authors:  Gian Paolo Rossi; Giuseppe Maiolino; Alberto Flego; Anna Belfiore; Giampaolo Bernini; Bruno Fabris; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Maria Lorenza Muiesan; Massimo Mannelli; Aurelio Negro; Gaetana Palumbo; Gabriele Parenti; Ermanno Rossi; Franco Mantero
Journal:  Hypertension       Date:  2018-02-26       Impact factor: 10.190

9.  Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

Review 10.  Regulation of Glucose Handling by the Skeleton: Insights From Mouse and Human Studies.

Authors:  Jian-Min Liu; Clifford J Rosen; Patricia Ducy; Stavroula Kousteni; Gerard Karsenty
Journal:  Diabetes       Date:  2016-11       Impact factor: 9.461
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.